ClinicalTrials.gg
CompletedNCT00632749Updated Sep 14, 2015Results posted

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

A Phase 2 interventional study of BI 811283 (d 1 and 15) and Cytarabine in Leukemia, Myeloid, Acute, sponsored by Boehringer Ingelheim. Completed at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-14.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Enrollment
85th of 239
68 · median 48
Started
2008
with 8 others
Phase 2
112 of 247
21 open now
Registered
72nd of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 85th largest by enrollment of the 239 interventional ones that give a count, is one of 9 that started in 2008, is one of 112 in phase 2, and was the 72nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML) patients

03

Conditions studied

  • Leukemia, Myeloid, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult with previously untreated acute myeloid leukaemia (AML)
  • Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL)
  • Patient is considered ineligible for intensive treatment
  • Patient is eligible for low-dose cytarabine (LD-Ara-C) treatment
  • > 3 months
  • Eastern co-operative oncology group (, R01-0787) performance score \<=2 at screening
  • Signed written consistent with international conference on harmonisation good clinical practice (ICH-GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  • Patient with APL (AML subtype M3 according to the French-American-British (FAB) classification).
  • or treatment refractory AML.
  • to one of the trial drugs or the .
  • Other requiring treatment.
  • Known central nervous system involvement.
  • Aspartate amino transferase () or alanine amino transferase (ALT) greater than 2.5 times the (ULN).
  • > 1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin).
  • greater than 1.5 mg/dl.
  • Serum creatinine greater than 2.0 mg/dl.
  • (Left ventricular ejection fraction) \< 50% in echocardiography or clinical congestive heart failure (NYHA) grade III or IV.
  • Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia.
  • Psychiatric illness or social situation that would limit compliance with trial requirements.
  • Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug (i.e. other chemo- or immunotherapy, see also section 4.2.2).
  • for cytarabine treatment according to the summary of product characteristics (SPC).
  • Patients who are sexually active and unwilling to use a medically acceptable method of during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.).
  • Pregnant or nursing female patients.
  • Patient unable to comply with the protocol.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Schedule A

    BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10

    Drug: BI 811283 (d 1 and 15) · Drug: Cytarabine

  • Experimental
    Schedule B

    BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10

    Drug: Cytarabine · Drug: BI 811283 (d1)

Interventions

  • DrugBI 811283 (d 1 and 15)

    BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle

  • Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle

  • DrugBI 811283 (d1)

    BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle

  • Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle

06

What researchers measure

Primary outcomes

  1. The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine.

    The MTD was defined as the highest dose at which 6 patients were treated and less than 2 patients who experienced a dose limiting toxicities (DLT) within the first cycle of treatment.The MTD was defined based on safety data from the first cycle only. It was determined using a standard "3 + 3 design with de-escalation".

    Time frame: up to 28 days of treatment

Secondary outcomes

  1. Response (Complete Remission [CR], Complete Remission With Incomplete Blood Count Recovery [CRi])

    Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria: The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. * Complete remission (CR): morphologically leukaemia free state (i.e. bone marrow with \< 5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥ 1,000/μL and platelets \> 100,000/μL. * Complete remission with incomplete blood count recovery ("incomplete" CR, CRi).All of the above criteria for CR had to be met, except that neutrophils \< 1,000/μL or platelets \< 100,000/μL in the blood.

    Time frame: Data collected up to cut-off date 20Oct2011, Up to 1239 days

  2. Incidence and Intensity of AEs Graded According to CTCAE (Version 3.0)

    The severity and timing of AEs indicates how well the treatment regimen was tolerated. Toxicities were evaluated using the common terminology criteria for adverse events (CTCAE) grading scheme.

    Time frame: Data from first treatment administration until cut-off date of 20 October 2011; up to 1239 days

  3. Incidence of Dose Limiting Toxicity (DLT)

    Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)

    Time frame: up to 28 days of treatment

  4. Partial Remission

    Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria; The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. Partial remission (PR). All of the criteria for CR had to be met, except that the bone marrow had to contain ≥ 5% but less than 25% blasts (or ≤ 50% of initial blast count), or \< 5% blasts in the presence of Auer rods or abnormal morphology.

    Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days

  5. Event Free Survival (EFS)

    EFS was defined as the duration of time from randomisation to time of treatment failure (i.e. PD), relapse from CR, or death from any cause, whichever came first.

    Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days

  6. Relapse Free Survival

    Relapse-free survival was defined only for patients who achieved CR/CRi and was measured from the date of attaining CR/CRi until the date of recurrence or death from any cause, whichever occurred first. Number of patients having relapse free survival are presented.

    Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days

  7. Remission Duration

    Remission duration analysis was defined only for patients who achieved CR, and was measured from the date of attaining CR until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of the cause.

    Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days

  8. Overall Survival (OS)

    OS was defined for all patients that entered the trial, and measured from the date of randomization until death from any cause.

    Time frame: Data collected up to cut-off date 20 Oct 2011, Up to 1239 days

  9. Cmax (Maximum Measured Concentration of BI 811283 in Plasma)

    Cmax (maximum measured concentration of BI 811283 in plasma) during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  10. AUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    AUC(0-inf) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  11. AUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

    AUC0-tz (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  12. Cmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State)

    Cmax (maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  13. AUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State

    AUC (0-inf, ss)(area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) at steady state during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  14. AUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State

    AUC (0-tz,ss) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) at steady state during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  15. Tmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma)

    tmax (time from dosing to maximum measured concentration of BI 811283 in plasma) during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  16. Tmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State)

    tmax,ss (time from dosing to maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1

    Time frame: -0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283

  17. Cmax (Maximum Measured Concentration of Cytarabine in Plasma)

    Cmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

    Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine

  18. Tmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma)

    Tmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

    Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine

  19. AUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    AUC (0-inf) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

    Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine

  20. AUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

    AUC (0-tz) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

    Time frame: -0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine

  21. Pharmacodynamic Monitoring

    Pharmacodynamic monitoring: drug effect on leukaemia cells (e.g. polyploidy, histone H3 phosphorylation, morphologic changes). An evaluation of this secondary endpoint is not possible due to missing samples / samples of poor quality of the provided material.

    Time frame: On Day 5, i.e. 72 hours after the end of the first BI 811283 infusion, and on Day 28 in the first cycle only

  22. Pharmacokinetics of Cytarabine After a Single Dose and at Steady State When Given Alone

    The study protocol originally included a phase II part with a treatment arm in which Cytarabine was given alone, however the sponsor discontinued the clinical development of BI 811283, therefore the protocol was amended and the reference therapy arm was removed from the study protocol" -\> (Protocol Amendment 5, version 19 -May-2010, approved 28-Jun-2010). Since there was never a treatment arm in which Cytarabine was given alone; hence pharmacokinetics are not calculated.

    Time frame: -0.05, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours

07

Results

Posted May 25, 2015

Participant flow

68 participants were entered, and 64 were treated with the study treatment

Participant flow — Overall Study
Milestone5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283+ 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Started45347854537436
Treated43347744537436
Not treated02000110000000
Completed00000000000000
Not completed45347854537436
Withdrew: Progressive disease32224432324324
Withdrew: Other adverse event11112412201010
Withdrew: Refuse to continue medication00010000010000
Withdrew: Reason other than those specified above02001010002102

Outcome measures

PrimaryThe Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine.

The MTD was defined as the highest dose at which 6 patients were treated and less than 2 patients who experienced a dose limiting toxicities (DLT) within the first cycle of treatment.The MTD was defined based on safety data from the first cycle only. It was determined using a standard "3 + 3 design with de-escalation".

Time frame:
up to 28 days of treatment
Reported as:
Number · mg
The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine.
mgTreatment Schedule ATreatment Schedule B
The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine.100NA
SecondaryResponse (Complete Remission [CR], Complete Remission With Incomplete Blood Count Recovery [CRi])

Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria: The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. * Complete remission (CR): morphologically leukaemia free state (i.e. bone marrow with \< 5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥ 1,000/μL and platelets \> 100,000/μL. * Complete remission with incomplete blood count recovery ("incomplete" CR, CRi).All of the above criteria for CR had to be met, except that neutrophils \< 1,000/μL or platelets \< 100,000/μL in the blood.

Time frame:
Data collected up to cut-off date 20Oct2011, Up to 1239 days
Reported as:
Number · participants
Response (Complete Remission [CR], Complete Remission With Incomplete Blood Count Recovery [CRi])
participants5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
CR00010110111010
CRi00000000000010
SecondaryIncidence and Intensity of AEs Graded According to CTCAE (Version 3.0)

The severity and timing of AEs indicates how well the treatment regimen was tolerated. Toxicities were evaluated using the common terminology criteria for adverse events (CTCAE) grading scheme.

Time frame:
Data from first treatment administration until cut-off date of 20 October 2011; up to 1239 days
Reported as:
Number · participants
Incidence and Intensity of AEs Graded According to CTCAE (Version 3.0)
participants5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
CTCAE Grade 100000000000000
CTCAE Grade 200100000000000
CTCAE Grade 311011010012100
CTCAE Grade 402224312313122
CTCAE Grade 530012422212214
SecondaryIncidence of Dose Limiting Toxicity (DLT)

Number of participants with DLT in the first cycle (28 days) for the determination of the maximum tolerated dose (MTD)

Time frame:
up to 28 days of treatment
Reported as:
Number · participants
Incidence of Dose Limiting Toxicity (DLT)
participants5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Incidence of Dose Limiting Toxicity (DLT)00000210001010
SecondaryPartial Remission

Response to treatment was evaluated according to the following criteria (modified from the National Cancer Institute/Cancer and Leukemia Group B criteria; The best overall response was defined as the best overall response recorded during the time period from the start of the treatment until the end of the treatment period, progression or death (whichever was earlier). Possible categories for best overall response were CR, CRi, Partial remission (PR), no change (NC), Progressive disease (PD) and no assessment. Partial remission (PR). All of the criteria for CR had to be met, except that the bone marrow had to contain ≥ 5% but less than 25% blasts (or ≤ 50% of initial blast count), or \< 5% blasts in the presence of Auer rods or abnormal morphology.

Time frame:
Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Reported as:
Number · participants
Partial Remission
participants5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Partial Remission00000001000000
SecondaryEvent Free Survival (EFS)

EFS was defined as the duration of time from randomisation to time of treatment failure (i.e. PD), relapse from CR, or death from any cause, whichever came first.

Time frame:
Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Reported as:
Mean · days
Event Free Survival (EFS)
days5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Event Free Survival (EFS)35.0 ± 15.6122.3 ± 120.032.0 ± 1.0117.5 ± 102.460.4 ± 52.662.0 ± 54.1209.0 ± 315.865.0 ± 41.5168.8 ± 219.362.7 ± 53.9138.7 ± 183.248.5 ± 36.9174.0 ± 67.230.0 ± 7.3
SecondaryRelapse Free Survival

Relapse-free survival was defined only for patients who achieved CR/CRi and was measured from the date of attaining CR/CRi until the date of recurrence or death from any cause, whichever occurred first. Number of patients having relapse free survival are presented.

Time frame:
Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Reported as:
Number · participants
Relapse Free Survival
participants5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Relapse Free Survival———1—11—111—2—
SecondaryRemission Duration

Remission duration analysis was defined only for patients who achieved CR, and was measured from the date of attaining CR until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of the cause.

Time frame:
Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Reported as:
Mean · days
Remission Duration
days5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283+ 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Remission Duration———263.0 ± NA—28.0 ± NA337.0 ± NA—455.0 ± NA—128.0 ± NA—15.0 ± NA—
SecondaryOverall Survival (OS)

OS was defined for all patients that entered the trial, and measured from the date of randomization until death from any cause.

Time frame:
Data collected up to cut-off date 20 Oct 2011, Up to 1239 days
Reported as:
Mean · days
Overall Survival (OS)
days5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Overall Survival (OS)122.8 ± 166.2212.0 ± 55.171.3 ± 40.5236.8 ± 225.5148.7 ± 125.586.6 ± 58.1236.8 ± 322.9137.3 ± 121.7198.2 ± 260.1339.7 ± 364.8175.7 ± 175.473.0 ± 31.3294.7 ± 101.548.7 ± 17.9
SecondaryCmax (Maximum Measured Concentration of BI 811283 in Plasma)

Cmax (maximum measured concentration of BI 811283 in plasma) during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Geometric mean · nmol/L
Cmax (Maximum Measured Concentration of BI 811283 in Plasma)
nmol/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine- Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120mg (BI 811283+ Cytarabine)- Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Cmax (Maximum Measured Concentration of BI 811283 in Plasma)8.03 ± 32.364.10 ± 686.0104.00 ± 321.0153.00 ± 108.0214.00 ± 38.8272.00 ± 30.07.06 ± 10.066.10 ± 85.3139.00 ± 33.8499.00 ± 101.0445.00 ± 71.0631.00 ± 31.0528.00 ± 40.51130.00 ± 53.3
SecondaryAUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

AUC(0-inf) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Geometric mean · nmol·h/L
AUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
nmol·h/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
AUC(0-inf) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity)177 ± 28.2985 ± 311.01000 ± 40.72790 ± 1304400 ± 62.95620 ± 27.9192 ± 47.71490 ± 98.12840 ± 29.68870 ± 59.99770 ± 63.014100 ± 32.612800 ± 64.323200 ± 57.9
SecondaryAUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

AUC0-tz (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Geometric mean · nmol·h/L
AUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
nmol·h/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
AUC0-tz (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)169 ± 30.5939 ± 3282010 ± 2072350 ± 1052810 ± 1355340 ± 27.2156 ± 17.51450 ± 97.32730 ± 29.18680 ± 60.49260 ± 63.613700 ± 31.712100 ± 63.121700 ± 55.2
SecondaryCmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State)

Cmax (maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Geometric mean · nmol/L
Cmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State)
nmol/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A
Cmax,ss (Maximum Measured Concentration of BI 811283 in Plasma at Steady State)8.02 ± 4.5924.7 ± 18.543.3 ± 5.58141 ± 52.2213 ± 96.1229 ± 67.9
SecondaryAUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State

AUC (0-inf, ss)(area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 extrapolated to infinity) at steady state during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Geometric mean · nmol·h/L
AUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State
nmol·h/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A
AUC (0-inf, ss)(Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 Extrapolated to Infinity) at Steady State188 ± 12.7615 ± 15.3NA ± NA4460 ± 41.85140 ± 105.04750 ± 58.1
SecondaryAUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State

AUC (0-tz,ss) (area under the concentration-time curve of BI 811283 in plasma over the time interval from 0 to the time of the last quantifiable data point) at steady state during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Geometric mean · nmol·h/L
AUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State
nmol·h/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A
AUC (0-tz,ss) (Area Under the Concentration-time Curve of BI 811283 in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) at Steady State183 ± 14.3597 ± 15.01620 ± 58.24330 ± 40.54340 ± 83.64820 ± 55.6
SecondaryTmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma)

tmax (time from dosing to maximum measured concentration of BI 811283 in plasma) during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Median · hours
Tmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma)
hours5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Tmax (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma)24.0 (6.0 to 24.1)26.0 (6.0 to 48.0)25.0 (24.0 to 32.0)22.7 (6.0 to 24.1)6.0 (4.1 to 24.3)23.6 (5.9 to 24.5)23.9 (4.0 to 24.2)6.0 (6.0 to 6.0)24.1 (6.0 to 26.8)24.9 (23.6 to 32.0)6.0 (6.0 to 25.0)23.9 (23.9 to 24.1)5.9 (4.8 to 6.0)14.8 (3.9 to 26.1)
SecondaryTmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State)

tmax,ss (time from dosing to maximum measured concentration of BI 811283 in plasma at steady state) during Cycle 1

Time frame:
-0.05 hours before and 1:00, 4:00, 6:00, 24:00, 25:00, 26:00, 28:00, 32:00, 36:00, 48:00 hours after administration of BI 811283
Reported as:
Median · hours
Tmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State)
hours5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A
Tmax,ss (Time From Dosing to Maximum Measured Concentration of BI 811283 in Plasma at Steady State)23.9 (4.1 to 23.9)24.0 (4.0 to 24.0)6.0 (4.0 to 24.0)6.0 (4.1 to 24.0)6.0 (5.9 to 23.5)6.0 (4.0 to 23.8)
SecondaryCmax (Maximum Measured Concentration of Cytarabine in Plasma)

Cmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

Time frame:
-0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Measured Concentration of Cytarabine in Plasma)
ng/mL5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Cmax (Maximum Measured Concentration of Cytarabine in Plasma)53.2 ± 65.472.6 ± 31.049.0 ± 80.664.9 ± 49.561.9 ± 57.346.0 ± 54.146.3 ± 31.849.8 ± 58.155.0 ± 16.565.1 ± 44.549.4 ± 58.948.6 ± 88.449.0 ± 77.068.7 ± 33.1
SecondaryTmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma)

Tmax of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

Time frame:
-0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
Reported as:
Median · hours
Tmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma)
hours5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Tmax (Time From Dosing to Maximum Measured Concentration of Cytarabine in Plasma)0.50 (0.50 to 1.0)0.50 (0.50 to 1.0)0.92 (0.50 to 1.0)0.83 (0.50 to 1.4)0.48 (0.42 to 0.53)0.55 (0.50 to 1.5)0.50 (0.40 to 0.70)0.50 (0.50 to 0.50)0.58 (0.47 to 1.0)0.50 (0.43 to 0.67)0.50 (0.45 to 1.0)0.50 (0.47 to 0.50)0.48 (0.48 to 1.0)0.49 (0.48 to 0.57)
SecondaryAUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

AUC (0-inf) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

Time frame:
-0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
Reported as:
Geometric mean · ng·h/mL
AUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
ng·h/mL5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
AUC (0-inf) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated to Infinity)104 ± 31.4122 ± 6.89102 ± 31.585.4 ± 35.365.9 ± 42.568.1 ± 41.462.0 ± 24.1NA ± NANA ± NA71.2 ± 20.772.7 ± 23.675.5 ± 27.276.9 ± 19.576.8 ± 42.6
SecondaryAUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

AUC (0-tz) of Cytarabine after a 20 mg Subcutaneous Dose on the First Day of BI 811283

Time frame:
-0.05 hours before and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours after administration of Cytarabine
Reported as:
Geometric mean · ng·h/L
AUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
ng·h/L5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
AUC (0-tz) (Area Under the Concentration-time Curve of Cytarabine in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)45.0 ± 156.066.9 ± 73.866.8 ± 57.671.8 ± 26.446.6 ± 51.242.3 ± 64.345.9 ± 20.033.9 ± 245.057.0 ± 18.260.2 ± 30.452.5 ± 38.852.1 ± 42.141.3 ± 87.251.6 ± 38.1
SecondaryPharmacodynamic Monitoring

Pharmacodynamic monitoring: drug effect on leukaemia cells (e.g. polyploidy, histone H3 phosphorylation, morphologic changes). An evaluation of this secondary endpoint is not possible due to missing samples / samples of poor quality of the provided material.

Time frame:
On Day 5, i.e. 72 hours after the end of the first BI 811283 infusion, and on Day 28 in the first cycle only

No measurements were reported for this outcome.

SecondaryPharmacokinetics of Cytarabine After a Single Dose and at Steady State When Given Alone

The study protocol originally included a phase II part with a treatment arm in which Cytarabine was given alone, however the sponsor discontinued the clinical development of BI 811283, therefore the protocol was amended and the reference therapy arm was removed from the study protocol" -\> (Protocol Amendment 5, version 19 -May-2010, approved 28-Jun-2010). Since there was never a treatment arm in which Cytarabine was given alone; hence pharmacokinetics are not calculated.

Time frame:
-0.05, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00 hours

No measurements were reported for this outcome.

Adverse events

Collected over Data from first treatment administration until cut-off date of 20 October 2011; up to 1239 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A—3/4 (75%)4/4 (100%)
15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A—2/3 (66.7%)3/3 (100%)
30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A—3/3 (100%)3/3 (100%)
60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A—4/4 (100%)4/4 (100%)
100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A—6/7 (85.7%)7/7 (100%)
120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A—6/7 (85.7%)7/7 (100%)
5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—4/4 (100%)4/4 (100%)
40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—3/4 (75%)4/4 (100%)
80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—5/5 (100%)5/5 (100%)
160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—3/3 (100%)3/3 (100%)
240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—7/7 (100%)6/7 (85.7%)
300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—3/4 (75%)4/4 (100%)
360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—3/3 (100%)3/3 (100%)
420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B—5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
Event5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
Febrile neutropeniaBlood and lymphatic system disorders0/40/31/32/42/70/73/41/41/51/32/72/42/32/6
General physical health deteriorationGeneral disorders0/40/30/31/40/72/70/40/41/52/33/71/40/30/6
PyrexiaGeneral disorders1/42/30/31/40/70/72/41/40/51/30/70/40/30/6
C-reactive protein increasedInvestigations0/40/30/31/41/71/70/40/41/52/31/70/40/30/6
Multi-organ failureGeneral disorders0/40/30/30/40/71/70/42/40/50/30/70/40/30/6
PneumoniaInfections and infestations2/40/30/32/42/71/71/42/42/50/32/70/41/31/6
SepsisInfections and infestations1/40/30/30/40/71/70/40/40/51/31/72/40/30/6
LeukocytosisBlood and lymphatic system disorders0/40/30/30/41/70/70/40/40/51/30/70/40/30/6
Acute myocardial infarctionCardiac disorders0/40/30/30/40/70/70/40/40/51/31/70/40/30/6
Atrial fibrillationCardiac disorders0/40/30/30/40/70/70/40/40/51/30/70/40/30/6
Most frequent other events
Showing 10 of 375
Most frequent other events
Event5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B
AnaemiaBlood and lymphatic system disorders1/42/31/31/45/75/71/42/41/53/33/71/43/33/6
LeukopeniaBlood and lymphatic system disorders0/40/31/31/44/75/71/41/41/51/33/72/43/32/6
NeutropeniaBlood and lymphatic system disorders0/40/30/30/41/71/70/40/41/51/31/70/43/32/6
NauseaGastrointestinal disorders2/42/30/32/43/74/71/41/43/52/31/73/43/32/6
FatigueGeneral disorders0/41/32/31/43/72/71/42/41/53/34/72/41/32/6
FallInjury, poisoning and procedural complications0/40/30/32/41/70/70/40/42/53/32/70/41/31/6
Blood potassium decreasedInvestigations0/40/30/31/45/74/70/40/40/51/33/71/43/31/6
DyspnoeaRespiratory, thoracic and mediastinal disorders0/41/31/30/42/74/71/42/41/53/35/70/40/32/6
ThrombocytopeniaBlood and lymphatic system disorders0/42/31/32/42/72/72/43/43/52/32/72/42/32/6
Abdominal painGastrointestinal disorders0/40/30/31/41/72/73/40/41/51/33/70/41/31/6

Baseline characteristics

68 participants were randomised, and 64 were treated with the study treatment hence the number of participants differs from the number of participants that started in the participant flow.

Age, Continuous
Age, Continuous(years)5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule BTotal
Mean76.0 ± 5.871.3 ± 2.579.3 ± 8.477.5 ± 4.067.4 ± 9.372.3 ± 5.174.3 ± 4.173.5 ± 6.679.0 ± 4.478.3 ± 4.072.3 ± 4.469.5 ± 11.863.3 ± 5.163.3 ± 5.672.2 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B80 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule BTotal
Female3222431322220230
Male1112343131523434
08

Study locations

7 sites
  • 1247.3.49007 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1247.3.49005 Boehringer Ingelheim Investigational Site
    Frankfurt/Main, Germany
  • 1247.3.49004 Boehringer Ingelheim Investigational Site
    Freiburg, Germany
  • 1247.3.49006 Boehringer Ingelheim Investigational Site
    Hamburg, Germany
  • 1247.3.49003 Boehringer Ingelheim Investigational Site
    Heidelberg, Germany
  • 1247.3.49002 Boehringer Ingelheim Investigational Site
    Münster, Germany
  • 1247.3.49001 Boehringer Ingelheim Investigational Site
    Ulm, Germany
09

References and documents

Publications

  • Dohner H, Muller-Tidow C, Lubbert M, Fiedler W, Kramer A, Westermann J, Bug G, Schlenk RF, Krug U, Goeldner RG, Hilbert J, Taube T, Ottmann OG. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. Br J Haematol. 2019 May;185(3):583-587. doi: 10.1111/bjh.15563. Epub 2018 Nov 19. No abstract available. PubMed 30450591 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year 2 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2008
First posted
Mar 11, 2008
Start
May 2008
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results delay requested
Apr 30, 2014
Results first posted
May 25, 2015
Last update
Sep 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00632749
Responsible party
Sponsor
First posted
Mar 11, 2008
Start date
May 2008
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
May 25, 2015
Last update
Sep 14, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytarabine

Start the discussion